The aim of the study is to evaluate the therapeutic efficiency of minoxidil solution iontophoresis on Androgenic Alopecia.

Hair is an important component of identity and self-image. Hair loss can lead to a variety of psychological difficulties and have a negative impact on quality of life (QoL). Loss of self-confidence lowered self-esteem, and heightened self-consciousness are common responses to hair loss, particularly for women. People with alopecia are more likely to develop depression and anxiety.

Some studies have proposed iontophoresis and ultrasound as energetic drug delivery methods to favor topical therapy of alopecia. Iontophoresis is a non-invasive technique that applies a small electric current (of no more than 0.5 mA/cm2) on the skin's surface to increase and control drug delivery. The technique is widely studied to stimulate the skin penetration and permeation of hydrophilic drugs, which would not be absorbed by the skin when passively applied. The transport of drugs through the skin as a result of the electric current is driven by two different mechanisms, ie, electromigration in the case of charged drugs and electroosmosis in the case of neutral drugs.

Furthermore the need of this study is developed from the lack in quantitative knowledge and information in published studies which investigate effect of minoxidil solution iontophoresis on Androgenic alopecia.

Inclusion Criteria:

• Twenty-five adult aged 18-65 with diagnosed androgenic alopecia.
• They diagnosed as Androgenic alopeacia by their physicians and referred for physical therapy management.
• Medically and psychologically stable patients.

Exclusion Criteria:

• History of hypersensitivity to minoxidil solution or Intophoresis.
• Scalp infection
• Concurrent hair loss treatments.
• Patients who suffer from hypertrophic and/or keloidal scars and a skin condition in the area of Androgenic alopecia that would interfere with study procedures.
• plaque psoriasis, tattoo, birthmark, facial hair.
• Patients with medical red flags as severe psychiatric disorder or cognitive deficits.
• Medically unstable and uncooperative patients.
• Immunocompromised status.
• History of skin cancer.
• Recurrent herpes viral infection.
• Pregnancy or breastfeeding status.